AbbVie Enters Second Vectorised Antibody Partnership with Voyager Therapeutics
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 3 (Table of Contents)
Published: 8 Mar-2019
DOI: 10.3833/pdr.v2019.i3.2410 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In its second multibillion-dollar alliance, Voyager Therapeutics has entered into another collaboration and option agreement with AbbVie to research, develop and commercialise adeno-associated virus and other-virus-based gene therapies for the treatment of Parkinson’s disease and other synucleinopathies...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS